ArticleFrontiers in medicine2026
Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy and safety of the MEK1/2 inhibitor trametinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and to explore potential clinical factors associated with treatment response. Methods: A retrospective analysis was performed on 20 patients with advanced NSCLC harboring the KRAS G12C mutation who were admitted to Heping Hospital, which is affiliated with Changzhi Medical College, from January 2020 to June 2023. After disease progression following first-line platinum-based doublet chemotherapy combined with PD-1/PD-L1 inhibitor therapy, all patients received 2 mg of trametinib orally once daily, with 21 days defined as one treatment cycle, until disease progression, death, or intolerable toxicity occurred. The primary endpoint was the objective response rate (ORR), and the secondary endpoints included the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse reactions. Results: Among the 20 patients, 16 were male, and 4 were female, with a median age of 65 years (range 51-78 years); 18 patients had a history of smoking, and the predominant histological type was adenocarcinoma (19 cases). The ORR was 27.8% (5/18), and the DCR was 72.2% (13/18). The median follow-up duration was 10.2 months, the median PFS was 3.8 months (95% CI: 2.9-4.7 months), and the median OS was 8.6 months (95% CI: 6.4-10.8 months). Univariate analysis indicated that the ORR of patients without bone metastasis was significantly greater than that of patients with bone metastasis (35.7% vs. 0%, Conclusion: Trametinib, as a second-line treatment for advanced NSCLC with a KRAS G12C mutation, has demonstrated evident anti-tumor activity, manageable toxicity, and favorable tolerability; exploratory analysis indicated that the absence of bone metastasis and PD-L1 positivity might be associated with improved outcomes. This regimen is highly clinically accessible and may serve as a second-line treatment option when KRAS G12C-specific inhibitors are unavailable. Its clinical value requires further validation through large-sample prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.